p75NTR Inhibitors
1 drugsAbout p75NTR
The p75 Neurotrophin Receptor (p75NTR) is a transmembrane protein in the tumor necrosis factor receptor superfamily. It interacts with neurotrophins like NGF, influencing cell survival, apoptosis, and differentiation through complex signaling pathways.
p75NTR is a therapeutic target with potential for intervention in various diseases. Currently, there is no genetic evidence data available linking p75NTR to specific diseases, warranting further research.
OXERVATE is the only FDA-approved drug targeting p75NTR, developed by DOMPE FARMACEUTICI. It is a biologic (other) modality and addresses a therapeutic area classified as 'Other'.
Top p75NTR Drugs
DOMPE FARMACEUTICI is the only company with an approved drug targeting p75NTR.
Low competition suggests high entry barrier or limited market interest.
p75NTR Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets p75NTR, using biologic (other) modality.
The absence of small molecule or antibody drugs represents a whitespace opportunity.
p75NTR Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on p75NTR. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 1 | 0 | 0% |
| Phase 3 | 4 | 2 | 0 | 2 | 100% |
| Phase 4 | 3 | 1 | 1 | 1 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
p75NTR Drug Approval Timeline (2018 - 2018)
OXERVATE was first approved in 2018 and remains the most recent approval.
The single approval indicates a potentially unsaturated market with room for growth.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on p75NTR. A trial counts if an approved drug acting on p75NTR is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.